deferoxamine / Generic mfg. - LARVOL DELTA

SLC22A17 affects the development of urethral stricture by promoting ferroptosis and inhibiting the activation of fibroblasts. (PubMed, Biochem Biophys Res Commun) - "Deferoxamine suppressed the SLC22A17 overexpression-mediated ferroptosis and the inactivation of primary urethral scar fibroblasts. Furthermore, the silencing of SLC22A17 inhibited the erastin-mediated ferroptosis and inactivation of primary urethral scar fibroblasts. These findings indicate that SLC22A17 may inhibit the fibrosis of urethral scar fibroblasts by promoting ferroptosis, thereby preventing the development of urethral stricture."

Journal • Fibrosis • Immunology • Urology • ACSL4 • GPX4 • SLC22A3

Targeting metabolic vulnerabilities in Acute Myeloid Leukemia: Therapeutic potential of l-asparaginase and synergy with venetoclax (ASH 2025) - "However, L-asp–induced lipid peroxidation wasminimal, and the annexin V positive cells induced by L-asp were only modestly suppressed by theferroptosis inhibitors liproxstatin-1 and deferoxamine. Alignedwith these findings, the combination of L-asp and venetoclax demonstrated marked synergisticcytotoxicity in these cell lines.In summary, AML with low ASNS expression shows high sensitivity to L-asp, suggesting that treatmentwith L-asp is an absolute indication. Furthermore, even in glutamine-dependent AML with high ASNSexpression, combination therapy with L-asp and venetoclax represents a promising therapeutic strategy."

IO biomarker • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • ANXA5 • BCL2

Coprogen B from Talaromyces marneffei ΔsreA: Rapid Iron Chelation and Favorable Partitioning to Deferoxamine. (PubMed, Int J Mol Sci) - "The siderophore exhibited greater lipophilicity, emphasizing better passive membrane permeability than DFO, while siderophore-Fe(III) binding indicated increased biases toward the aqueous phase. Future in vivo studies are warranted to confirm its pharmacokinetics, safety, and therapeutic efficacy."

Journal • Hematological Disorders

Size-Controlled Mesoporous Silica Nanoparticles via Template Nanoarchitectonics from a Deferoxamine Derivative for Enhanced Blood-Brain Barrier Permeability and Neuroprotective Chelation Therapy. (PubMed, ACS Appl Mater Interfaces) - "Furthermore, permeability studies using a Caco-2 in vitro BBB model revealed that a smaller particle size greatly enhances transport across the barrier. These results support DFO@MSNs as a promising multifunctional nanoplatform for targeted chelation therapy and neuroprotection in ND treatment."

Journal • CNS Disorders • Inflammation • Neuroblastoma • Oncology • Solid Tumor

Longitudinal monitoring of nanofibrillar cellulose hydrogel medical implants in mice using positron emission tomography. (PubMed, Eur J Pharm Sci) - "In this study, the relatively longer-lived positron-emitting radionuclide zirconium-89 was chelated to the octadentate deferoxamine (DFO*)-conjugated NFC hydrogel ([89Zr]Zr-DFO*-NFC) to enable longitudinal monitoring of its in vivo fate using positron emission tomography techniques...In contrast, mice receiving a control formulation of [89Zr]Zr-oxalate mixed with NFC hydrogel showed progressive accumulation of radioactivity in the bones, consistent with known [89Zr]Zr-oxalate distribution patterns, and only limited retention at the implant site by Day 7. These findings demonstrate that [89Zr]Zr-DFO*-NFC hydrogel implants exhibit high in vivo stability with negligible systemic release following subcutaneous implantation, supporting their potential use as safe and traceable biomaterial platforms."

Journal • Preclinical

68Ga radiolabeling strategies in Pt(IV)-deferoxamine scaffolds for potential theranostic application. (PubMed, Dalton Trans) - "Since the discovery of cisplatin's anticancer activity and its clinical approval in 1978, substantial efforts have focused on improving its physiological stability and minimizing off-target toxicity. Radiolabeling with Gallium-68 was achieved under mild conditions, yielding stable radiotracers in various biological media after 1 h incubation. This study represents one of the first demonstrations of Pt(IV) theranostic agents suitable for PET imaging, enabling future investigations of Pt(IV) biodistribution profiles that go beyond traditional therapeutic evaluations."

Journal • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Expression of proteins secreted by osteocytes in bone biopsies of patients with chronic kidney disease and iron overload, before and after treatment with deferoxamine. (PubMed, Bone) - "In patients with CKD and iron overload, deferoxamine treatment modulates bone remodeling and expression of osteocyte proteins, which also play a role in the process."

Journal • Chronic Kidney Disease • Hematological Disorders • Metabolic Disorders • Nephrology • Orthopedics • Renal Disease • DKK1 • FGF23

Erianin Disturbs Iron and ROS Homeostasis To Trigger Ferroptosis in Colorectal Cancer Cells. (PubMed, Cell Biochem Biophys) - No abstract available

Journal • Colorectal Cancer • Oncology • Solid Tumor

Daphnetin Alleviates Liver Fibrosis by Inducing Ferritinophagy-Mediated Ferroptosis in Activated Hepatic Stellate Cells. (PubMed, Phytother Res) - "However, deferoxamine (DFO) and Fer-1 partially abrogated the antifibrotic effect of Daph. Mechanically, Daph exerted an antifibrotic effect by ubiquitinating glutathione peroxidase 4 (GPX4) and stimulating ferritinophagy-mediated ferroptosis in HSCs. These results indicated that Daph promoted the ubiquitination of GPX4 and ferritinophagy-mediated ferroptosis in HSCs, which could provide new clues for further pharmacological research on the antifibrotic effect of Daph."

Journal • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Targeted Protein Degradation • GPX4

Hyperuricemia Exacerbates Myocardial Ischemia-Reperfusion Injury by Inducing Ferroptosis via NCOA4 and xCT-GPX4 Axis Dysregulation. (PubMed, Eur J Pharmacol) - "Specifically, nuclear receptor coactivator 4(NCOA4) expression was upregulated, while the levels of SLC7A11 (xCT), glutathione peroxidase 4(GPX4), and ferritin heavy chain 1(FTH1) were significantly reduced. Notably, treatment with ferroptosis inhibitors such as deferoxamine(DFO) and ferrostatin-1(Fer-1) effectively mitigated these pathological changes, underscoring the contribution of NCOA4-FTH1 and xCT- glutathione (GSH)-GPX4 signaling to hyperuricemia-aggravated MI/RI ."

Journal • Cardiovascular • Metabolic Disorders • Myocardial Ischemia • Reperfusion Injury • GPX4 • NCOA4 • SLC7A11

27-Hydroxycholesterol triggers microglial senescence subsequent to iron over-loading contributes to brain aging, suppressed by Deferoxamine. (PubMed, NPJ Aging) - "Deferoxamine (DFX) mitigated microglial senescence and ferroptosis. These findings establish the 27-OHC-iron axis as a novel therapeutic target for combating cholesterol-driven neurodegeneration."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Hematological Disorders • Inflammation • Mood Disorders • Psychiatry • CDKN1A • DMRT1 • GPX4

ELOVL5 Regulates Ferroptosis in Breast Cancer Cells. (PubMed, Dokl Biochem Biophys) - "In this work, the effect of ELOVL5 knockdown on the dynamics of ferroptosis induction in MDA-MB-231 cells under the influence of docosahexaenoic acid (DHA) and erastin was investigated...The protective effect of ferroptosis inhibitors (ferrostatin-1 and deferoxamine) confirmed the involvement of this pathway in the observed effects. Differences in the expression of genes associated with oxidative stress, inflammation and proliferation were also revealed, indicating different molecular trajectories of ferroptosis in cells with different ELOVL5 gene expression. Thus, the present study deepens the understanding of the contribution of the ELOVL5 gene to the regulation of ferroptosis and can be used in the development of targeted therapy for breast cancer."

Journal • Breast Cancer • Oncology • Solid Tumor

Deferoxamine alleviates brain ischemia/reperfusion injury through decreasing LAG-3 and α-Syn expression. (PubMed, Can J Physiol Pharmacol) - "In conclusion, brain ischemia is associated with iron accumulation that promotes α-Syn expression and aggregation potentially through increasing LAG-3 expression which improved after deferoxamine injection. In addition this study illuminates the future beneficial targeting of LAG-3 in brain ischemia."

IO biomarker • Journal • Cardiovascular • Ischemic stroke • Reperfusion Injury • LAG3

Ferroptosis Targeting Offers a Therapeutic Strategy for Subarachnoid Hemorrhage. (PubMed, CNS Neurol Disord Drug Targets) - "Natural products (e.g., dihydroquercetin and ginsenoside Rd), synthetic ferroptosis inhibitors (e.g., ferrostatin-1 and deferoxamine), nanomedicines, and small molecules (e.g., melatonin and semaglutide) exert neuroprotective effects by targeting ferroptosis pathways, including the glutathione (GSH)-glutathione peroxidase 4 (GPX4) axis, Nrf2 signaling, iron chelation, and lipid peroxidation suppression. The findings of this study underscore the therapeutic potential of ferroptosis inhibition as a novel strategy to ameliorate EBI-SAH and provide a foundation for future translational research."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Subarachnoid Hemorrhage • Vascular Neurology • GPX4

Engineering a therapeutic deferoxamine-mesoporous silica-naringin/poly(L-lactic acid) scaffold to reverse ferroptosis-mediated imbalance and promote osteogenic differentiation in osteoporotic microenvironment. (PubMed, Int J Biol Macromol) - "A co-culture system with mBMSCs and macrophages under iron-overloaded conditions further confirmed the scaffold's ability to enhance bone formation by mitigating ferroptosis and reprogramming the immune microenvironment. This innovative scaffold design offers a promising strategy for osteoporotic bone defects treatment by simultaneously addressing iron overload, inflammation, and impaired osteogenesis."

Journal • Hematological Disorders • Immunology • Inflammation • Osteoporosis • Rheumatology

The Challenge of Healing Wounds in Radiation-Injured Skin. (PubMed, Adv Wound Care (New Rochelle)) - "These include dermal substitutes, placental derivatives, fibronectin, injectable fat-derived and plasma-derived compounds, hyperbaric oxygen, and deferoxamine...Future Directions: Treatments leveraging recent insights into collateral radiation injury may help to condition tissue to promote healing/regeneration of wounds. Although animal studies and human case reports have been promising, wide-scale clinical studies examining their efficacy are still needed before many of these novel strategies may be adopted to help the millions of patients worldwide suffering from radiation-related cutaneous wounds."

Journal • Review • Fibrosis • Immunology

Deferoxamine improves femoral trochlear dysplasia following patellar dislocation through HIF-1α/VEGF-mediated angiogenesis-osteogenesis coupling. (PubMed, J Orthop Surg Res) - "HIF-1α/VEGF-mediated angiogenesis-osteogenesis coupling plays an important role in trochlear dysplasia following PD. Intra-articular injections of DFO improve trochlear morphology, bone microstructure, and reduce cartilage degeneration by stabilizing HIF-1α to upregulate VEGF and osteogenic markers (RUNX2, ALP, OPN)."

Journal • COL2A1 • HIF1A • RUNX2 • VEGFA

Role of ferroptosis-related GPX4 signaling in the fusion of human trophoblast cells. (PubMed, Sci Rep) - "To address the impact of ferroptosis signaling on syncytialization, forskolin-stimulated trophoblast BeWo cells were treated with GPX4 inhibitors RSL3, ML-210, or erastin...These effects were suppressed by deferoxamine, an iron chelator, and ferrostatin-1, a lipid peroxidation inhibitor, both of which significantly reduced hCGβ expression...Inhibition of the ER stress sensors IRE1α and ATF6 attenuated hCGβ expression, implicating these pathways in the regulation of syncytialization. Collectively, these findings suggest that ferroptosis-related lipid peroxidation and iron signaling contribute to the regulation of trophoblast fusion, potentially physiological role in placental development."

Journal • ATF6 • GPX4 • KEAP1

Radiolabeling of CHX-A″-DTPA-Antibody Conjugates with [89Zr]ZrCl4. (PubMed, J Nucl Med) - "Currently, the most applied 89Zr-immuno-PET platform is the [89Zr]Zr-deferoxamine (DFO)-monoclonal antibody (mAb) constructs, where the investigational agent is obtained through combining [89Zr]Zr-oxalate with mAbs conjugated to the bifunctional chelator p-SCN-Bn-DFO... Pertuzumab was selected for proof-of-concept studies and was conjugated to p-SCN-Bn-CHX-A″-DTPA... The ability to radiolabel CHX-A″-DTPA-mAbs with 89Zr has been demonstrated, allowing for the generation of 89Zr/177Lu/161Tb-based true radiotheranostic pairs. On the basis of our biodistribution data, [89Zr]Zr-DTPA-mAbs may be better suited as a companion diagnostic to radiotherapeutic DTPA-mAb analogs than is [89Zr]Zr-DFO-mAbs."

Journal • Oncology

ATP-binding cassette B8 prevents endothelial dysfunction and atherosclerosis. (PubMed, Redox Biol) - "Combination of intravital imaging experiments with ex vivo treatment of aortae from Abcb8ECKO with the iron chelator deferoxamine or TGF-β receptor I inhibitor SB431542 suggests that ABCB8 suppresses iron-dependent TGF-β-mediated vascular inflammation in the aorta. In agreement, endothelial ABCB8 deficiency exacerbates atherosclerosis and hypertension in Apoe-/- knockout mice, uncovering a critical atheroprotective role for ABCB8 and supporting its therapeutic potential in vascular disease."

Journal • Atherosclerosis • Cardiovascular • Hypertension • Inflammation • Metabolic Disorders • APOE • TGFB1

Combination of iron chelator deferoxamine and ABCG2 transporter inhibitor lapatinib for therapeutic enhancement of 5-aminolevulinic acid. (PubMed, Photochem Photobiol) - "Not just increasing ALA-PpIX levels, Lap enhanced PpIX localization in the mitochondria and promoted mitochondria-mediated apoptosis after PDT in the H4 cell line with strong ABCG2 activities. Our results demonstrate that blocking ABCG2-mediated PpIX efflux is critical for the enhancement of ALA and, in tumor cells with ABCG2 activities, inhibiting PpIX bioconversion by DFO needs to be combined with PpIX efflux suppression for effective enhancement of ALA."

Journal • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • ABCG2

Birnessite Dissolution at the Mineral-Ligand Interface: A Deferoxamine Pathway. (PubMed, Langmuir) - "The transient Mn(III) formed appears to coordinate with DEFO, and is subsequently reduced further to Mn(II), resulting in the formation of a Mn(II)-DEFO complex. These results indicate that DEFO is oxidized while birnessite's manganese is reduced (Mn(IV) → Mn(III) → Mn(II)), with radical intermediates observed."

Journal

Iron Chelation Efficiency in Human Hepatocytes Is Enhanced By Exogenous Hepcidin (ASH 2023) - "Here we have examined whether application of exogenous hepcidin to a human hepatocyte cell line HepG2 can increase the chelation efficiency of deferiprone and whether this effect is also seen with other iron chelators such as deferasirox and deferoxamine. Two mechanisms for enhanced chelation are possible in this model; the first is by increased iron loading of hepatocytes incubated with hepcidin and secondly through the blocking by hepcidin of labile intracellular iron egress through ferroportin channels, thereby increasing the magnitude of chelatable intracellular iron pools. Future work in primary human hepatocytes will examine whether manipulation of intracellular hepcidin levels by SLN124 has similar chelation-enhancing effects."

Beta-Thalassemia • Genetic Disorders • Hematological Disorders • TMPRSS6

Advanced glycated end-products modified transferrin mediates oxidative stress and ferroptosis in podocytes via advanced glycation end-product receptor in vitro. (PubMed, Sci Rep) - "Podocytes were treated with AGE-Tf produced at different concentrations of glucose, and rescue experiments include AGE-Tf + deferoxamine mesylate (DFO), AGE-Tf + Ferrostatin-1 (Fer-1, inhibitors of ferroptosis), and AGE-Tf + advanced glycation end-product receptor (RAGE) antagonist peptide (RAP) groups...Whereas the addition of Fer-1 or RAP reduced the effects of AGE-Tf on podocytes, including oxidative stress and ferroptosis, which were inhibited, and cell viability and apoptosis rate were partially improved. AGE-Tf may mediate oxidative stress and ferroptosis in podocytes via AGE/RAGE."

Journal • Preclinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • ACSL4 • GPX4 • SLC7A11

Iron Deficiency in Drosophila melanogaster Glial Cells Impacts Behavior Through Altered Mitochondrial Dynamics. (PubMed, J Neurochem) - "ID induced by dietary deferoxamine altered locomotor activity in adult flies...These findings demonstrate, for the first time, the importance of iron availability in Drosophila glial cells and its impact on behavior and mitochondrial dynamics. Most importantly, the Drosophila model proves useful in unveiling previously unknown cellular and molecular mechanisms associated with ID in glial cells."

Journal • Hematological Disorders